SCHEMBL4756407

SCHEMBL4756407

CCCCS(=O)(=O)c1cnc(NC(=O)c2ccccc2O)s1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 2/20 0.51
MEN1 O00255 8/20 0.46
KMT2A Q03164 8/20 0.46
NPC1 O15118 6/20 0.46
RAB9A P51151 6/20 0.46
RXFP1 Q9HBX9 1/20 0.46
GRM4 Q14833 5/20 0.45
KDM4E B2RXH2 2/20 0.44
TP53 P04637 2/20 0.44
HTT P42858 2/20 0.44
ALDH1A1 P00352 2/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
RCE1 Q9Y256 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NAAA Q02083 1/20 0.43
CRHBP P24387 2/20 0.43
CRHR2 Q13324 2/20 0.43
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4756880 0.89 GRM4 (0.45) STAT3MEN1KMT2ANPC1RAB9A
SCHEMBL19978237 0.85 ALDH1A1 (0.54) MEN1KMT2ANPC1RAB9AGRM4
SCHEMBL4756409 0.84 ALDH1A1 (0.57) STAT3MEN1KMT2ANPC1RAB9A
SCHEMBL31426452 0.82 STAT3 (0.58) STAT3MEN1KMT2ANPC1RAB9A
SCHEMBL704075 0.82 STAT3 (0.58) STAT3MEN1KMT2ANPC1RAB9A
SCHEMBL4757140 0.81 GRM4 (0.45) STAT3MEN1KMT2ANPC1RAB9A
SCHEMBL4756451 0.76 CCNE1 (0.52) STAT3MEN1KMT2ANPC1RAB9A
SCHEMBL4756532 0.75 STAT3 (0.60) STAT3MEN1KMT2ANPC1RAB9A
SCHEMBL16918852 0.75 GRM4 (0.42) STAT3MEN1KMT2ANPC1RAB9A
SCHEMBL2696756 0.75 STAT3 (0.53) STAT3MEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9820975-B2 Compounds and methods for treating influenza ROMARK LABORATORIES L.C. (US) 2017-11-21 US disclosed
US-9820975-B2 Compounds and methods for treating influenza ROMARK LABORATORIES L.C. (US) 2017-11-21 US disclosed
US-20160228415-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES L.C. (US) 2016-08-11 US disclosed
US-9345690-B2 Compounds and methods for treating influenza ROMARK LABORATORIES L.C. (US) 2016-05-24 US disclosed
US-20150250768-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES L.C. (US) 2015-09-10 US disclosed
US-8895752-B2 Alkylsulfonyl-substituted thiazolide compounds ROMARK LABORATORIES L.C. (US) 2014-11-25 US disclosed
US-20120122939-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS ROMARK LABORATORIES, L.C. 2012-05-17 US disclosed
US-8124632-B2 Alkylsulfonyl-substituted thiazolide compounds ROMARK LABORATORIES, L.C. (US) 2012-02-28 US disclosed
US-20090036467-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS ROMARK LABORATORIES L.C. 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150250768-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA HIF1AN, HAVCR2, NEU1 STAT3 2441/4885MEN1 3237/4885KMT2A 2029/4885
US-20160228415-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA HIF1AN, HAVCR2, NEU1 STAT3 2441/4885MEN1 3237/4885KMT2A 2029/4885
US-20120122939-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS HAVCR2, EIF2AK2, AADAC STAT3 63/4885MEN1 4564/4885KMT2A 2303/4885
US-20090036467-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS HAVCR2, EIF2AK2, AADAC STAT3 63/4885MEN1 4564/4885KMT2A 2303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.